ArticlePloS one2026
Methylation-specific, universal, and highly sensitive identification of ctDNA in prostate cancer by multiplex droplet digital PCR.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of a Methylated Circulating Tumour DNA Panel for Detection and Disease Stratification in Prostate Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLiquid biopsy for detection of circulating tumor DNA (ctDNA) offers a promising, non-invasive strategy for real-time monitoring of cancer. We aimed to develop a universal and sensitive one-tube droplet digital PCR (ddPCR) multiplex assay able to detect ctDNA in plasma from metastatic prostate cancer (PCa) patients.
methodsPublicly available array data are applied to identify methylation signatures specific to both normal and cancerous prostate tissue. The assay is based on the highly sensitive ddPCR technology, and tissue and plasma samples are analyzed using the QX600 ddPCR multiplexing platform from BioRad.
resultsWe identified three novel genomic regions, ACTRT2, EVX1, and HOXD13, containing CpG-methylation signatures specific to normal and cancerous prostate tissue. We successfully targeted the three biomarkers in a single-tube methylation-specific multiplex ddPCR (mm-ddPCR) assay along with two previously reported PCa-specific hypermethylated CpG biomarkers, DOCK2 and HAPLN3, and the ALB reference gene. The mm-ddPCR assay consistently detected ACTRT2, EVX1, and HOXD13 across all samples originating from prostate-derived tissue. In contrast, the HAPLN3 and DOCK2 biomarkers were predominantly detected in PCa tissue. We also demonstrate that the five ctDNA biomarkers can be detected in plasma samples from metastatic castration-resistant PCa (mCRPC) patients with a 95% CI (85%, 100%) using the mm-ddPCR assay.
conclusionThis work demonstrates that the mm-ddPCR assay offers a simple, fast, cost-effective, sensitive, and universal tool for the detection of ctDNA biomarkers in plasma from mCRPC patients. Further studies are required to explore its potential for PCa risk stratification and treatment guidance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.